SSA
AKBA icon

Schonfeld Strategic Advisors’s Akebia Therapeutics AKBA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,550
Closed -$25.5K – 2031
2023
Q4 		$25.5K Buy
+20,550
New +$21K ﹤0.01% 1691

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Schonfeld Strategic Advisors's AKBA Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2024, closing a stake of 20,550 shares — an estimated $25.5K sold.

Schonfeld Strategic Advisors first reported a position in AKBA in Q4 2023 and held it in 1 quarter. The position peaked at $25.5K in Q4 2023. 114 funds tracked by Wall St. Rank hold AKBA as of Q1 2024.

  • Schonfeld Strategic Advisors reported no remaining Akebia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 20,550 Akebia Therapeutics shares in Q1 2024, an estimated $25.5K.
  • Schonfeld Strategic Advisors first reported a position in Akebia Therapeutics in Q4 2023 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Akebia Therapeutics position peaked at $25.5K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.